19:27 , Nov 16, 2018 |  BC Week In Review  |  Company News

Boehringer, Epizyme to develop small molecules against epigenetic cancer targets

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with Epizyme Inc. (NASDAQ:EPZM) to develop small molecule inhibitors of two undisclosed epigenetic cancer targets in the helicase and histone acetyltransferase (HAT) families. The companies plan to focus on...
23:23 , Nov 15, 2018 |  BC Extra  |  Company News

Boehringer, Epizyme to develop small molecules against epigenetic cancer targets

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with Epizyme Inc. (NASDAQ:EPZM) to develop small molecule inhibitors of two undisclosed epigenetic cancer targets in the helicase and histone acetyltransferase (HAT) families. The companies plan to focus on...
03:19 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
17:14 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Constellation raises $60M in NASDAQ IPO

Epigenetics company Constellation Pharmaceuticals Inc. (NASDAQ:CNST) raised $60 million on July 18 through the sale of 4 million shares at $15 in a downsized IPO. Underwriters are J.P. Morgan, Jefferies, BMO Capital Markets and Oppenheimer....
17:52 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest transferrin-conjugated liposomal nanoparticles loaded with temozolomide and an inhibitor of BET bromodomain proteins could help treat glioma. The liposomal nanoparticles contain distearoylglycerophosphoethanolamine (DSPE) conjugated to polyethylene glycol (PEG) and...
10:59 , Apr 9, 2018 |  BC Extra  |  Financial News

Constellation raises $100M venture round

Cancer epigenetics company Constellation Pharmaceuticals Inc. (Cambridge, Mass.) raised $100 million in an untranched venture round from new investors Cormorant Asset Management, Deerfield Management, Fidelity Management, Hillhouse Capital, NS Investment, OrbiMed and Sirona Capital. Existing...
23:08 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies suggest inhibiting CDK9 could help treat castration-resistant prostate cancer (CRPC) that is resistant to BET bromodomain protein inhibitors. In a human BET inhibitor-resistant CRPC cell line, siRNA targeting CDK9...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
21:27 , Oct 26, 2017 |  BC Innovations  |  Tools & Techniques

Ripe for enhancement

Although still largely the purview of academics, technologies for mapping enhancers to the genes they control are rapidly gaining efficiency and promise to unlock a trove of new targets for drug developers. But companies will...
19:51 , Oct 26, 2017 |  BC Innovations  |  Translation in Brief

HATs off to epigenetics

Although the epigenetics field is heating up, most compounds on the market and in development are clustered around the same small set of targets. Now, a team led by AbbVie Inc. (NYSE:ABBV) has uncovered an...